The first generic of Restasis is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Avalere’s examination of Medicare Part D plan tier placement of generic prescription drugs found that over time their percentage on generic tiers has declined from 65% in 2016 to 43% in 2022.
The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.